ClinicalTrials.gg
RecruitingNCT06643130Updated Sep 9, 2025

Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia

A Phase 3 interventional study of JW0104+C2402 and JW0104+C2403 in Hypertension and Dyslipidemia, sponsored by JW Pharmaceutical. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by JW Pharmaceutical · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 353 studies in Hypertension with a site in Korea, Republic of — 30 open to participants now, 41 under way, 11 of them phase 3. Hypertension · Korea, Republic of.

Planned enrollment
116th of 304
162 · median 110
Started
2024
with 14 others
Phase 3
92 of 353
9 open now
Primary completion
2026-04
later than 20 of 40 live
Registered
322nd of 353
by date

Among the 353 studies in Hypertension with a site in Korea, Republic of, this one is the 116th largest by planned enrollment of the 304 interventional ones that give a count, is one of 15 that started in 2024, is one of 92 in phase 3, reaches primary completion later than 20 of the 40 other live ones, and was the 322nd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

30 of the 353 studies in Hypertension with a site in Korea, Republic of are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 353 studies in Hypertension with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients with Hypertension and Dyslipidemia

Read the detailed description

To evaluate the efficacy and safety of co-administration of JW0104+C2402 in comparison with co-administration of JW0104+C2403 or C2402 alone in patients with hypertension and dyslipidemia.

03

Conditions studied

  • Hypertension
  • Dyslipidemia
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with hypertension and dyslipidemia

Exclusion criteria

Exclusion Criteria:

  • The subject not meet the specified msBP and LDL-C level
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
162 participants (estimated)

Study arms

  • Experimental
    JW0104+C2402

    JW0104+C2402, 8 weeks, QD (Quaque Die)

    Drug: JW0104+C2402

  • Active comparator
    JW0104+C2403

    JW0104+C2403, 8 weeks, QD

    Drug: JW0104+C2403

  • Active comparator
    C2402

    C2402, 8 weeks, QD

    Drug: C2402

Interventions

  • DrugJW0104+C2402

    For 8 weeks(PO (Per Oral), QD)

    Also known as: NA (Not Applicable)

  • DrugJW0104+C2403

    For 8 weeks(PO, QD)

    Also known as: NA (Not Applicable)

  • DrugC2402

    For 8 weeks(PO, QD)

    Also known as: NA (Not Applicable)

06

What researchers measure

Primary outcomes

  1. Change from baseline in msSBP (Systolic Blood Pressure)

    Check msSBP

    Time frame: week 8

  2. Percent change from baseline in LDL-C (Low-Density Lipoprotein Cholesterol)

    Check LDL-C

    Time frame: week 8

Secondary outcomes

  1. change from baseline in msSBP

    Check msSBP

    Time frame: week 4

  2. Change and percent change from baseline in LDL-C

    Check LDL-C

    Time frame: week 4

07

Study locations

1 of 1 sites recruiting
  • Gangdong Sacred Heart Hospital
    Seoul, 05355, South Korea
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Apr 2026, 16 months after the start.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's planned 16 months is below that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 16, 2024
StartActual
Dec 2, 2024
Primary completionEst.
Apr 2026
CompletionEst.
Apr 2026
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06643130
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
Oct 16, 2024
Start date
Dec 2, 2024
Primary completion
Apr 2026 (estimated)
Completion
Apr 2026 (estimated)
Last update
Sep 9, 2025

Study contacts

Minjung Kim
Contact
kmj@jwhealthcare.com
+82-2-840-6861
Dongryung Lee
Contact
dongryung.lee@jwhealthcare.com
+82-2-840-6982
Minjung Kim
study chair · JW Pharmaceutical

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion